We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...

We recently compiled a list of the 10 ... Last year, GSK reported nearly halving its net profit after settling hefty US lawsuits over its Zantac heartburn drug. Net income after tax dropped ...

Glaxo (GSK) delivered earnings and revenue surprises of 11.32% and 4.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...

Cancer patients to receive relief on imported medicines through Basic Customs Duty exemptions and patient assistance programmes.

Subsidies and existing MediSave schemes could possibly bring the out-of-pocket cost of Shingrix down to zero, says Health ...

The list for the next round of medicines that will ... reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process.

Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer treatment Calquence, GSK’s chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta, and ...

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...

The list of 15 medicines includes blockbuster drugs from Novo Nordisk, Pfizer, Bristol Myers Squibb, AstraZeneca, GSK and other companies. Novo’s booming semaglutide franchise for diabetes and ...

We recently compiled a list of the 12 ... GSK plc (NYSE:GSK) is advancing several promising assets in oncology and respiratory, including B7-H3 and B7-H4 antibody-drug conjugates for difficult ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.